0
     

Global Markets Direct

Global Markets Direct

Total Post Count: 15 of 3209


Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Toll Like Receptor 4 (hToll or CD284 or TLR4) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Toll Like Receptor 4 (hToll or CD284 or TLR4) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Alpha N-Acetylglucosaminidase (N Acetyl Alpha Glucosaminidase or NAGLU or EC 3.2.1.50) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Alpha N-Acetylglucosaminidase (N Acetyl Alpha Glucosaminidase or NAGLU or EC 3.2.1.50) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Kidney Cancer (Renal Cell Cancer) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Kidney Cancer (Renal Cell Cancer) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Non-Small Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Non-Small Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Ovarian Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Ovarian Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Colorectal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Colorectal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update